Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04438382 · ClinicalTrials.gov registry record · Phase 2
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
A Phase 2 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04438382 is a Phase 2 study that was terminated before completion, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1 participants.
The verdict
NCT04438382, a Phase 2 study, was terminated before completion, sponsored by ECOG-ACRIN Cancer Research Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating patients with pneumonitis.
Interventions
- BIOLOGICAL Infliximab
- DRUG Prednisone
- DRUG Methylprednisolone
- BIOLOGICAL Intravenous Immunoglobulin Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04438382
The ClinicalTrials.gov registry entry for NCT04438382 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Infliximab is the first listed.
NCT04438382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04438382 about?
NCT04438382 is a clinical study titled "Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis". This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere wit...
What is the current status of trial NCT04438382?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-01-07. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT04438382?
The interventions under investigation include: Infliximab (BIOLOGICAL), Prednisone (DRUG), Methylprednisolone (DRUG), Intravenous Immunoglobulin Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04438382?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.